SEC Tracker
Get the app

Omeros OMER

Omeros FY 2024: net loss $156.8M; diluted EPS −$2.70

Form
10-K/A
Filed
Period
Importance
Routine
Document
10-K/A

Key figures from this report

These are the numbers Omeros reported for the year ended Dec 31, 2024, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Net income−$156.8MAgainst −$117.8M in FY 202310-K income statement, on EDGAR
  2. Diluted EPS−$2.70Against −$1.88 in FY 202310-K income statement, on EDGAR
  3. Cash and cash equivalents$3.4M−52% from $7.1M in FY 2023Cash and equivalents only; the company page adds short-term investments.10-K balance sheet, on EDGAR
  4. Cash from operations−$148.8M−299% from $74.7M in FY 202310-K cash flow statement, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when Omeros files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Lexicon Pharmaceuticals LXRX public float $170M, Jun 30, 2025
  2. XOMA Royalty XOMA public float $168M, Jun 30, 2025
  3. Crescent Biopharma CBIO public float $177M, Jun 30, 2025
  4. 4D Molecular Therapeutics FDMT public float $166M, Jun 30, 2025
  5. Lineage Cell Therapeutics LCTX public float $162M, Jun 30, 2025